Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
17.00
-0.43 (-2.47%)
At close: Aug 21, 2026, 4:00 PM EDT
16.75
-0.25 (-1.47%)
After-hours: Aug 21, 2026, 7:42 PM EDT
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
$807,210
Profits / Employee
-$1,165,062
Market Cap
2.20B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vera Therapeutics | 361 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 305 |
| UroGen Pharma | 300 |
| Harmony Biosciences Holdings | 293 |
| Aurinia Pharmaceuticals | 128 |
| Nanobiotix | 100 |
| Rapport Therapeutics | 84 |
MESO News
- 6 days ago - Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing - International Business Times (Australia)
- 6 days ago - Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial - TheFly
- 6 days ago - Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 24 days ago - Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch - GlobeNewsWire
- 5 weeks ago - Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 5 weeks ago - Mesoblast reported Q4 Ryoncil net revenue of $36M - TheFly
- 5 weeks ago - Mesoblast rises 6.2% - TheFly
- 6 weeks ago - Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 - GlobeNewsWire